Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.75 |
| ▸ | GMNN | O75496 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901660 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL22930771 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL21118752 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL23895049 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL22928985 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL23635844 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL24722613 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL25098577 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL20822086 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL21886761 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2023-01-24 | — | — | US | disclosed |
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213592-B2 | Antibody-sting agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | STING1 1/4885LMNA 2981/4885RAPGEF3 582/4885 |
| US-20210290774-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | STING1 1/4885LMNA 2981/4885RAPGEF3 582/4885 |
| US-11559537-B2 | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists | CASP1, CASP2, APAF1 | STING1 388/4885LMNA 718/4885RAPGEF3 635/4885 |
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | STING1 388/4885LMNA 718/4885RAPGEF3 635/4885 |
| US-11033635-B2 | Antibody-STING agonist conjugates and their use in immunotherapy | STING1, CGAS, MAVS | STING1 1/4885LMNA 2981/4885RAPGEF3 582/4885 |
| US-20210015941-A1 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | STING1, CGAS, MAVS | STING1 1/4885LMNA 2981/4885RAPGEF3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.